BioStem Technologies, Inc.
BSEM
$4.02
$0.112.68%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 399.87% | 589.29% | 474.04% | 1,719.76% | 884.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 399.87% | 589.29% | 474.04% | 1,719.76% | 884.58% |
| Cost of Revenue | -42.18% | 34.10% | 263.74% | 975.24% | 1,333.70% |
| Gross Profit | 500.69% | 694.61% | 487.16% | 1,781.93% | 818.93% |
| SG&A Expenses | 921.66% | 941.88% | 420.93% | 982.13% | 71.20% |
| Depreciation & Amortization | 10.03% | 7.34% | 0.40% | -3.32% | -8.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 631.72% | 743.50% | 411.74% | 961.87% | 131.10% |
| Operating Income | -25.81% | 116.14% | 3,943.31% | 450.58% | 297.47% |
| Income Before Tax | -21.12% | 162.81% | 1,268.28% | 385.71% | 265.65% |
| Income Tax Expenses | -183.26% | -192.32% | -239.98% | -- | -- |
| Earnings from Continuing Operations | 48.29% | 398.82% | 954.04% | 397.57% | 215.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.29% | 398.82% | 954.04% | 397.57% | 216.48% |
| EBIT | -25.81% | 116.14% | 3,943.31% | 450.58% | 297.47% |
| EBITDA | -66.47% | 35.76% | 3,945.19% | 363.65% | 303.92% |
| EPS Basic | 48.16% | 446.91% | 748.71% | 344.37% | 192.29% |
| Normalized Basic EPS | -66.19% | 46.44% | 1,128.22% | 296.08% | 246.85% |
| EPS Diluted | 32.99% | 553.21% | 510.51% | 276.88% | 167.03% |
| Normalized Diluted EPS | -70.22% | 50.07% | 673.99% | 252.25% | 210.47% |
| Average Basic Shares Outstanding | 3.94% | 8.04% | 12.97% | 20.09% | 21.60% |
| Average Diluted Shares Outstanding | 16.99% | 26.75% | 52.94% | 59.19% | 46.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |